Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction.

@article{Wendt2008DiscoveryOA,
  title={Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction.},
  author={Michael D. Wendt},
  journal={Expert opinion on drug discovery},
  year={2008},
  volume={3 9},
  pages={1123-43}
}
BACKGROUND The discovery of ABT-263, a rationally designed Bcl-2/Bcl-xL inhibitor at present in Phase I clinical trials for cancer, is described. Emphasis is placed on the specific hurdles overcome throughout the discovery process that relate to the nature of the targeted protein-protein interaction (PPI). OBJECTIVE/METHODS This review draws on observations from the experience of discovering ABT-263 and discusses them within the framework of the larger issue of discovering drugs targeting… CONTINUE READING